anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Safety Run-In (Cohort 1): Participants will receive a 2-week lead in of atezolizumab in combination with paclitaxel, followed by ipatasertib in an initial 28-day (1 cycle) period. Atezolizumab will be administered via IV infusion on Days 1 and 15, with paclitaxel administered by IV infusion on Days 1, 8 and 15. Ipatasertib will be administered orally daily on Days 15-21. In all subsequent treatment cycles, ipatasertib will be administered orally daily on Days 1-21, paclitaxel will be administered by IV infusion on Days 1, 8, and 15 and atezolizumab will be administered by IV infusion on Days 1 and 15. All participants in this cohort will continue to be treated until loss of clinical benefit, unacceptable toxicity, or withdrawal of consent.
This will be an open label, phase IV study. After appropriate consent, 132 premature infants born at \<35 weeks gestation (i.e. up to 34 weeks and 6 days), 50% \<30 weeks gestation (i.e. up to 29 weeks and 6 days) will be randomised to 1 of 2 4CMen B schedules either at 2,4 and 12 months or 2,3,4 and 12 months. Babies will remain in the study for around 12 months, from recruitment to 13 months of age. All visits can be performed at the participant's home or in clinic, depending on the preference of the parents and study team.

Blood samples will be obtained at 5 months of age (post primary sample), 12 months (persistence sample) and 13 months (post booster sample). Reactogenicity and safety will be assessed by caregiver completion of a 7-day diary after each vaccine dose. Inpatients will be monitored for cardiorespiratory events for 72 hours after vaccination by healthcare staff and this information will be collected on the CRF. This will include details of oxygen saturations, heart rate, respiratory rate and details of any episodes of desaturation, bradycardia or apnoea. Particular emphasis will be placed on rates, timing and intensity of fever and other adverse reactions in the first 24 hours after vaccination, because this remains a cause of great concern amongst neonatologists.
Inherited retinal diseases (IRDs) are extremely heterogeneous with at least 350 causative genes, complicating the process of genetic diagnosis. We analyzed samples of 252 index cases with IRDs using the Blueprint Genetics panel for "Retinal Dystrophy" that includes 351 genes. The cause of disease could be identified in 55% of cases. A clear difference was obtained between newly recruited cases (74% solved) and cases that were previously analyzed by panels or whole exome sequencing (26% solved). As for the mode of inheritance, 75% of solved cases were autosomal recessive (AR), 10% were X-linked, 8% were autosomal dominant, and 7% were mitochondrial. Interestingly, in 12% of solved cases, structural variants (SVs) were identified as the cause of disease. The most commonly identified genes were ABCA4, EYS and USH2A, and the most common mutations were MAK-c.1297_1298ins353 and FAM161A-c.1355_1356del. In line with our previous IRD carrier analysis, we identified heterozygous AR mutations that were not the cause of disease in 36% of cases. The studied IRD panel was found to be efficient in gene identification. Some variants were misinterpreted by the pipeline, and therefore, multiple analysis tools are recommended to obtain a more accurate annotation of potential disease-causing variants.
PURPOSE:To mold sticklike cosmetics of good quality in a simple apparatus without contamination of air, by bringing a special molding block into close contact with a vessel containing a liquid raw material composition of a solid cosmetic, inserting and filling the liquid raw material composition in a filling hole of the above-mentioned block, and solidifying and drying the filled raw material composition. CONSTITUTION:A molding block 5 having plural sticklike filling holes 4 with both opened ends formed in the upward and downward directions is brought into close contact with the interior of an annular rising part 3 formed around a vessel 2 containing a liquid raw material composition 1 of a solid cosmetic by a suitable means, and the filled liquid raw material composition 1 is compressed and made to flow into the filling holes 4. The excess liquid raw material composition 1 is made to flow into a recess part 8 of the top, and the filling holes 4 are filled. The liquid raw material composition 1 is then solidified and dried, and the molding block 5 is removed from the rising part 3 of the vessel 2 to push out the resultant sticklike cosmetics from the filling holes 4. The above-mentioned apparatus is usable in good conditions without causing a trouble for a long term, and is suitable for molding the rapidly curable liquid raw material composition of high viscosity, e.g. eyebrow pencil, lipstick or stick foundation, etc.
BACKGROUND: Some pulmonary tuberculosis patients may require lung resection surgery. Postoperative pulmonary rehabilitation is essential to restore the lung function and maintain quality of life. We aimed to study the pulmonary rehabilitation outcomes and complications of step-by-step Baduanjin exercise under a doctor-nurse-patient integration mode in patients after lobectomy due to pulmonary tuberculosis.
METHODS: We performed a randomized controlled clinical trial in patients undergoing lobectomy due to pulmonary tuberculosis between September 2017 and August 2021. Eligible patients were randomly assigned into the control group or interventional group. The control group received routine postoperative care. The interventional group received step-by-step Baduanjin exercise based on the doctor-nurse-patient integration mode in addition to the routine care. The primary outcomes were the pulmonary functions, including forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and FEV1/FVC. The secondary outcomes were the maximum walking distance in a 6-min walk test and postoperative pulmonary complications, including atelectasis, pneumonia, and respiratory failure.
RESULTS: A total of 100 patients were enrolled into the study, with 50 patients in the control and interventional groups. There were 60 female patients (60%). The mean patient age was 37.9 (± 2.8) years old. At the one- and two-month postoperative follow-ups, pulmonary function tests showed statistically significantly better performances in FEV1/prediction, FVC/prediction, and FEV1/FVC in the interventional group than the control group. The 6-min walk test also revealed longer walking distances in the interventional group than the control group. There were no statistically significant differences in postoperative complications between the two groups.
CONCLUSIONS: A step-by-step Baduanjin exercise regimen under the doctor-nurse-patient integration mode could safely improve pulmonary rehabilitation in patients after lobectomy due to pulmonary tuberculosis.
The study will be conducted with 400 volunteer participants aged 18-39 years old. Participants will be asked to collect urine samples over a 24-hour period. One-third of the participants (n=133) will be asked to collect a second 24-hour urine 4-11 days later. A 24-hour dietary recall interview will be collected after the completion of each 24-hour urine collection. Results from this study will be used to assess how well the sodium excretion estimated from NHANES timed urine correlates with data from 24-hour urine collection. It will provide valuable information on the potential of NHANES timed urine collections to be used to characterize trends in U.S. population sodium intake.
Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
Tricaprilin SD formulation, single dose (20g caprylic triglyceride). Administered orally.
This randomized controlled trial included patients over 18 years of age with knee pain persisting for more than 3 months and stage II-III knee OA according to the Kellgren-Lawrence scale. The participants were randomized into two groups: the IAPRF + steroid injection (Group 1) and only steroid injection (Group 2) groups. The injections were administered under fluoroscopic guidance in both groups, and the needle was advanced to the midline of the tibiofemoral joint in the anteroposterior and lateral views. Group 1 received 8 mg of intra-articular dexamethasone after IAPRF application for 360 s at 45 V voltage, with the temperature not exceeding 42°C. Group 2 received 8 mg of intra-articular dexamethasone only. Pain intensity and participation in daily activities were evaluated using the numerical rating scale (NRS) and Western Ontario and McMaster Universities arthritis index (WOMAC), respectively, before the procedure and 1, 4, and 12 weeks after the procedure.
This is a prospective cohort study to find out the role of plasma I-FABP level, SOFA score, fluid balance, and vasopressor dose in predicting gastrointestinal dysfunction in high-risk postoperative patients treated in ICU. The characteristics of patients who meet the eligibility criteria were obtained. Blood sampling during admission is done for I-FABP level measurement and will be repeated after 24 hours. Blood sample which is not directly processed will be stored in refrigerator under 6-8C temperature. Evaluation of Acute Gastrointestinal Injury signs and symptoms is done. The re-evaluation is performed every day. If patients experiencing AGI signs and symptoms, monitoring and treatment based on condition are done. Routine follow-up is continued during hospitalisation in ICU. After all sample are collected, I-FABP level is assessed quantitatively using ELISA.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, particularly to pharmacy. There is disclosed new preparation. Controlled-release Proxodolol is prepared effectively and conveniently with applying one or more mixed swelling or gelling components, an active component and pharmaceutically acceptable filler. It is preferential to apply a tableted preparation containing Proxodolol dosed 120 mg, hypromellose and pharmaceutically acceptable fillers, e.g. microcrystalline cellulose, calcium stearate and aerosil. New pharmaceutical forms with a suitable Proxodolol release profile allow reducing number of daily dosages while concentration of active component is constant within a therapeutic dose. ^ EFFECT: stable kinetic indicators of active material delivery. ^ 8 cl, 5 ex, 5 tbl
OBJECTIVE: The purpose of this study was to examine whether the relative frequency of leading causes and total associated costs of readmission after acute ischemic stroke changed with Medicaid expansion, and how these changes differed by racial/ethnic group.
METHODS: We used a difference-in-differences approach to compare changes in the relative frequency of leading causes of unplanned 30-day readmission and to examine changes in the costs associated with unplanned readmission between expansion states (AR, MD, NM, and WA) and non-expansion states (FL and GA). To estimate the differential effect of Medicaid expansion by race/ethnicity on the causes and cost of readmission, we added a time*treatment*race interaction. Multinomial logistic regression was performed to analyze the changes in readmission cause. Gamma log-link modeling was used to study changes in readmission costs for expansion compared to non-expansion states.
RESULTS: The final multinomial model showed an association between expanded Medicaid and the relative frequency of sepsis readmission for White patients. According to predictive margins, White patients in expansion states had an estimated increase of 3.3 percentage points in the share of readmissions for sepsis but not for White patients in non-expansion states. In contrast, non-White patients in expansion states had a decrease of 1.8 percentage points in the share of readmissions for sepsis. Overall, Medicaid expansion was associated with a net increase of 6.7 percentage points in the share of readmissions for sepsis among non-Hispanic Whites relative to all other groups. In the final gamma model, Medicaid expansion was associated with a decrease in readmission costs overall. According to predictive margins, the net cost reduction in expansion versus non-expansion states was an average of $2509.
CONCLUSIONS: Medicaid expansion is associated with an overall decrease in unplanned readmission costs and an increase among readmitted White patients in the likelihood of readmission for sepsis.
Allopurinol is a xanthine oxidase inhibitor. It has the following structural formula:

Allopurinol is known chemically as 1, 5-dihydro-4 H-pyrazolo [3, 4-d]pyrimidin-4-one. and it has a molecular weight of 136.11 g/mol. Its solubility in water at 37°C is 80.0 mg/dL and is greater in an alkaline solution. It is a xanthine oxidase inhibitor which is administered orally. 

Each scored white to off white round tablet contains 100 mg allopurinol and the inactive ingredients crospovidone, colloidal silicon dioxide, lactose monohydrate, magnesium stearate, pregelatinized starch, and povidone. 

Each scored peach round tablet contains 300 mg allopurinol and the inactive ingredients crospovidone, colloidal silicon dioxide, FD&C Yellow No. 6 Lake, lactose monohydrate, magnesium stearate, pregelatinized starch and povidone.
A newly developed tool to guide clinicians in best palliative care practices was developed based on a combination of published tools and consultation with primary care, end users (clinicians). The tool will be introduced as a pilot to clinicians who will receive training on use of the tool and access to the tool within a family health team in Ontario, Canada. The tool will be applied in a controlled study environment that randomly assigns clinicians to one of two groups. One group will receive training and access to the tool and the other group of clinicians will continue to provide usual care.The tool will be evaluated based on validated satisfaction surveys completed by caregivers, patients and clinicians. Satisfaction scores of those randomly assigned to care enhanced by the tool will be compared to those receiving usual care at the beginning and end of the study. Uptake of the tool will be measured, as well as user experience with the tool (feasibility and acceptability)
UNLABELLED: The aim of this study was to develop age- and sex-specific reference data for body composition parameters, including fat-free mass (FFM), body cell mass (BCM), fat mass (FM) and related indices, fat mass percentage (FM%), total body water (TBW) and muscle mass (MM) and to assess differences in these parameters between male and female adolescents. Bioelectrical impedance analysis (BIA) data were obtained from an ethnically homogeneous sub-sample of 4037 normal-weight participants selected on the basis of BMI from the total sample (2005 males and 2032 females aged 10-18 years) of the ADOPOLNOR study, a cross-sectional population-based survey conducted in western Poland. The LMS method and RefCurv version 0.4.2 software package were used to calculate centile values and plot smoothed centile curves. The results showed age-related changes in body composition parameters and a clear sexual dimorphism. From the age of 13 (for FFM) or 14 (for BCM, BCMI and MM) or throughout adolescence (for TBW and FFMI), boys had consistently higher values for these parameters than girls (p < 0.01 for each). However, they had significantly lower values for FM, FMI and FM% (1.3, 1.6 and 1.5 times lower at 18 years, respectively), indicating a lower proportion of body fat than girls (p < 0.01 for each). The centile values and curves were specific for boys and girls of all ages. Compared with other European adolescent cohorts, the data fit the normal-weight subsamples better than the population reference data.
CONCLUSION: This study provides reference data for body composition in normal (healthy) weight Polish adolescents, providing a contextualised framework that takes into account the unique physiological and environmental factors of the region. These reference data may also be useful for other Central European adolescents.
WHAT IS KNOWN: • Adolescence is a period of significant physical growth and increased susceptibility to nutritional problems due to factors such as suboptimal nutrition, unhealthy dietary choices, inadequate physical activity and psychosocial stressors related to body image concerns. • Body composition (BC) parameters, rather than BMI alone, are more effective in identifying nutritional abnormalities and health risks such as eating disorders, obesity and chronic diseases. Existing studies provide reference data for BC parameters, but often do not cover all relevant measures or specific regional populations.
WHAT IS NEW: • This study provides new age- and sex-specific reference values for a comprehensive range of body composition parameters, including body cell mass (BCM), total body water (TBW) and muscle mass (MM), in addition to fat-free mass (FFM) and fat mass (FM), in a large, ethnically homogeneous, normal-weight population of Polish adolescents aged 10-18 years. • These reference values for the normalweight cohort reflect healthy adolescent growth and body composition patterns, minimising bias from abnormal weight status. In addition, they can be applied to other Central European adolescent populations.
Monitoring of invasive blood pressure and / or cardiac output of resuscitation patients is required and recommended. The installation of an arterial catheter in intensive care is very frequent and subject to many complications. These complications are now well recognized in the literature, they are mainly vascular, infectious and thrombotic. They are directly influenced by the number of attempts to puncture and the time taken to perform the gesture. Many measures are taken to reduce the impact such as the choice of the site of installation, the strict aseptic techniques during the installation and the type of catheter used. However, despite these measures, it appears that the incidence of these complications remains high. Compared to anatomical marking, only the technique of laying the ultrasound-guided catheter has shown its effectiveness in reducing these complications. The management in intensive care of increasingly complicated, severe, elderly patients with significant comorbidities increases from year to year. To the knowledge of the investigator, there is no study on the impact of ultrasound arterial catheterization in patients in resuscitation.
Both patients with functional dyspepsia and healthy controls will be asked to fill out ESM questionnaires during 1 week. Moreover, at the end of this week, usual questionnaires for complaints assessment will be filled out.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: application relates to composition for application of sugar coatings by method of spraying directly on core material with obtaining of hard drug form. According to invention, composition includes water and hard component, representing mixture of sugar, binding agent, hydroxyalkylcellulose, water-soluble polymer, therapeutic agent, second polymer, which is water-soluble or dispersible in water and plasticiser. Invention also relates to hard drug form, in particular, tablet for peroral introduction, which has described above coating, and as therapeutic agent, in core material contains conjugated estrogens. Invention also relates to method of said sugar coating application, which includes core obtaining, application of coating composition on core material and in case of necessity application of colour and glossy coatings. ^ EFFECT: invention ensures obtaining coatings which demonstrate good mechanical strength and elasticity when applied on substrate, thus reducing probability of cracks development; in addition, application of water-soluble system in coating composition makes it possible to minimise application of organic solvents in process of film coating application. ^ 110 cl, 1 dwg, 11 ex
The overall objective of this project is to develop, evaluate, and disseminate a web application called Check-up and Choices (CC). CC will be developed for use in primary care. It would tightly integrate screening for heavy drinking and drug use, a brief motivational intervention for hazardous or heavy drinkers, a moderation training protocol for less dependent problem drinkers, and an abstinence-oriented protocol for more dependent drinkers and drug abusers. The brief motivational intervention will be tailored to the patient's age. Its purpose will be to motivate problem drinkers to change their drinking. The action-oriented moderation and abstinence protocols are cognitive-behavioral interventions (CBIs) that provide patients with the skills to maximize their chances of success with changing their drinking and/or drug use.

The investigators have already developed these elements but they are not integrated into a single program with appropriate branching between them. Nor has the content been tailored for use in primary care.
Patients of Control Group received FZQZ-Placebo 20ml every time, and three times a day combined with integrated therapy.The integrated therapy was as follows: (1)low-protein dietary with sufficient calorie supply.(2) Anti-hypertensive agents to achieve a systolic blood pressure of less than 140 mm Hg and a diastolic blood pressure of less than 90 mmHg.(3)Anti-hyperlipidemic agentsas necessary to achieve low-density lipoprotein cholesterol（LDL-CH）less than 2.6mmol/L and triglycerides less than1.7mmol/L.（4）Patients with Diabetes Mellitus received insulin or oral hypoglycemic agents to achieve HbA1c 6.5～8.0%. (5)Received Sodium Bicarbonate as necessary to achieve serum HCO3-≥22mmol/L.(6) Received ferrous succinate, folic acid, and erythropoietin to achieve HB 90\~110g/L.
The invention relates to a medicament, in particular to a sofosbuvir tablet and a preparation method thereof. The sofosbuvir tablet comprises the following components: a complex made of sofosbuvir and an alcohol sugar. The preparation method comprises the following steps: and (3) dissolving the sofosbuvir and the alcohol sugar into a mixed solution obtained in alcohols, placing the mixed solution into ethers to separate out the compound, mixing the compound with an excipient, and tabletting to obtain the sofosbuvir tablet. The Sofosbuvir tablet provided by the invention comprises the compound prepared from Sofosbuvir and the alcohol sugar, so that the Sofosbuvir tablet can be presented in smaller weight and size, is easy to swallow, and has a high dissolution rate of more than 85% in 5 min. The invention prepares the compound from the sofosbuvir and the alcohol sugar, and then prepares the sofosbuvir tablet with the excipient. Wherein, the compound is prepared by the Sofosbuvir and the alcohol sugar, so that the preparation method is simplified and the dissolution performance is optimized.
Safety run-in phase: Participants with previously untreated or relapsed or refractory FL will receive obinutuzumab (G) and bendamustine during Cycle 1 (28-day cycle) and atezolizumab, obinutuzumab, and bendamustine during Cycles 2-6, during induction treatment, followed by atezolizumab (once monthly) and obinutuzumab (every other month \[q2m\]) for 24 months, during maintenance treatment. Expansion phase: Participants with previously untreated FL will receive same treatment regimen as described for safety run-in phase.
Participants receive intravenous saline at one study visit for 100 minutes total. The volume of saline will match the volume of angiotensin-(1-7) infused. Infusion rates will be calculated for each patient based on body mass. Saline will be given in escalating doses for 10 minutes each and then held for 70 minutes at the highest dose.